Study to Assess the Occurrence of HPA-1a Alloimmunization in Women With Higher Risk for Fetal and Neonatal Alloimmune Thrombocytopenia
NCT ID: NCT05345561
Last Updated: 2025-11-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
14390 participants
OBSERVATIONAL
2022-03-14
2025-10-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pregnant women
Women with higher risk of FNAIT
Clinical data collection
Laboratory tests, Vital assessments, Maternal and fetal genotype testing, Antibodies Testing will be performed.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Clinical data collection
Laboratory tests, Vital assessments, Maternal and fetal genotype testing, Antibodies Testing will be performed.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rallybio
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
New Horizons Clinical Trials, LLC
Chandler, Arizona, United States
Zillan Clinical Research - Gardena
Gardena, California, United States
Yale University School of Medicine
New Haven, Connecticut, United States
University of Miami Miller School of Medicine
Miami, Florida, United States
Cooper University Hospital
Camden, New Jersey, United States
Robert Wood Johnson Medical School
New Brunswick, New Jersey, United States
St. Peter's University Hospital
New Brunswick, New Jersey, United States
Rutgers New Jersey Medical School
Newark, New Jersey, United States
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Columbia University Irving Medical Center
New York, New York, United States
New York-Presbyterian-Queens
New York, New York, United States
Weill Cornell Medicine-New York Presbyterian Hospital
New York, New York, United States
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
Ohio State University Wexner Medical Center
Columbus, Ohio, United States
Wright State Physicians Obstetrics & Gynecology
Dayton, Ohio, United States
Temple Perinatal Diagnosis Center
Philadelphia, Pennsylvania, United States
Javara Inc. - Forest
Dallas, Texas, United States
The University of Texas Health Science Center at Houston
Houston, Texas, United States
Javara Research Inc. - Dallas - PPDS
Houston, Texas, United States
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Klinikum der Friedrich Schiller Universität Jena
Jena, Thuringia, Germany
Leids Universitair Medisch Centrum
Leiden, South Holland, Netherlands
Oslo Universitetssykehus HF, Ullevål
Oslo, Oslo County, Norway
Universitetssykehuset Nord Norge
Tromsø, , Norway
Barnmorskestationen Rosengård
Lund, Skåne County, Sweden
Södersjukhuset
Stockholm, Stockholms Ian, Sweden
Clinical Trial Consultants - Uppsala
Uppsala, Uppsala Ian, Sweden
St. Thomas' Hospital
London, Surrey, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IPA2002
Identifier Type: -
Identifier Source: org_study_id